CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue. Key points:

• Also known as DAC:GRF (Drug Affinity Complex:Growth Hormone-Releasing Factor)
• Composed of 30 amino acids
• Molecular formula: C152H252N44O42
• Molecular weight: 3367.954 g/mol
• Developed by ConjuChem Biotechnologies
• Modified form of GHRH (1-29) with improved pharmacokinetics, especially half-life

CJC-1295 works through several mechanisms:

• 1 Binds to GHRH receptors in the anterior pituitary gland
• 2 Stimulates the pulsatile release of growth hormone
• 3 Increases the amplitude of growth hormone pulses
• 4 Enhances production of insulin-like growth factor 1 (IGF-1)
• 5 Maintains more consistent blood levels of growth hormone

• Increases plasma GH levels by 2- to 10-fold for 6 days or longer
• Elevates plasma IGF-1 levels by 0.5- to 3-fold for 9 to 11 days

• Potential to reduce body fat
• May increase lean muscle mass
• Could improve overall body composition

• May accelerate wound healing
• Potential to enhance recovery from exercise and injuries

• May improve sleep quality and duration
• Potential to enhance deep sleep phases

• Possible improvements in memory and mental clarity
• Potential neuroprotective effects

• Typical dose: 1000-2000 mcg per week
• Often divided into 1-2 doses

• Higher dose: 2000-3000 mcg per week
• Usually divided into 1-2 doses

• Lower dose: 1000-1500 mcg per week
• Often administered 1-2 times weekly

• Dose range: 30-60 mcg per kg of body weight
• Typically administered 1-2 times weekly

• Typical dose: 100-200 mcg before bed
• Can be used consistently or cycled 5 days on, 2 days off

• 1 Use bacteriostatic water to reconstitute the lyophilized powder
• 2 Add water slowly, allowing it to trickle down the side of the vial
• 3 Gently swirl the vial to mix, avoid shaking to prevent protein denaturation
• 4 Calculate the correct dosage based on concentration (e.g., 2000 mcg/ml)
• 5 Use sterile syringes and needles for each injection
• 6 Recommended needle size: 29-31 gauge, 1/2 inch length

• Common injection sites: abdomen (2 inches away from navel), thigh, or upper arm
• Rotate injection sites to prevent irritation
• Administer on an empty stomach or at least 2 hours after eating
• For optimal results, avoid eating for 1-2 hours post-injection

• Popular combination for enhanced GH release
• Typical dosage: 1000 mcg CJC-1295 + 300 mcg Ipamorelin, administered together
• May increase GH release synergistically

• May provide complementary effects
• Dosages should be adjusted when combined (typically 1000 mcg CJC-1295 + 100-200 mcg GHRP)

CJC-1295 is typically only available through licensed medical professionals or specialized research chemical suppliers. Always ensure you're obtaining CJC-1295 from a reputable source that provides third-party testing results.

Generally considered safe when used as directed, but potential side effects include:

• Injection site reactions (redness, swelling)
• Headaches
• Flushing
• Nausea
• Water retention
• Increased insulin sensitivity

Long-term safety data is limited, and use should be monitored by a healthcare professional.

• Not approved by the FDA for human use
• Legal status varies by country and jurisdiction
• Often restricted to research or medical use
• Banned by WADA for competitive athletes
• In the US, it's legal to possess for research purposes but not for human consumption
• Always check local laws before purchasing or using CJC-1295

• Store lyophilized powder at room temperature (20-25°C or 68-77°F) away from light
• Once reconstituted, store in the refrigerator (2-8°C or 36-46°F)
• Use within 30 days after reconstitution
• Do not freeze reconstituted CJC-1295
• Always use sterile techniques when handling

Results may vary, but some users report noticeable changes within 4-8 weeks of consistent use. Improved sleep and recovery may be noticed within the first few weeks, while changes in body composition typically take 2-3 months to become apparent.

While not primarily a weight loss drug, CJC-1295 may contribute to fat loss as part of its effects on body composition and metabolism.

Long-term safety data is limited. Use should be monitored by a healthcare professional. Some studies have shown safe use for up to 12 months, but regular health check-ups and blood tests are recommended.

CJC-1295 DAC includes a Drug Affinity Complex that extends its half-life to about 8 days, compared to the 30-minute half-life of regular CJC-1295.

• CJC-1295 shows promise as a potent growth hormone secretagogue with potential benefits for body composition, recovery, and anti-aging. The typical dosage range of 1000-3000 mcg per week appears effective for most applications, with specific dosages tailored to individual goals and responses.
• Its ability to increase growth hormone levels for extended periods makes it an attractive option for those seeking the benefits of increased GH without the need for daily injections. However, its use should be approached cautiously due to limited long-term safety data and varying legal status.
• Always consult with a healthcare professional before starting any peptide regimen, and ensure regular monitoring of health markers during use. As research continues, our understanding of CJC-1295's full potential and optimal use protocols may evolve.

• 1 Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
• 2 Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
• 3 Sackmann-Sala L, et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
• 4 Alba M, et al. (2006). Once-weekly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analogue, normalizes growth in growth hormone-deficient rats. Growth Hormone & IGF Research, 16(5-6), 326-334.
• 5 Jetté L, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification